02.Feb.2012

Interim analysis has been completed on phase III trial in ovarian cancer, 75% of patients included in the IA

This is FDA controlled study conducted in 86 sites around the world. OCT is responsible for sites in Russia, Ukraine, Belarus, Latvia, Lithuania, Estonia and Bulgaria. In total, our CRO is responsible for more than 60 oncology sites across Eastern Europe.75 % of all patients were enrolled in OCT countries.

OCT is participating in ovarian cancer trial.

This is FDA controlled study conducted in 86 sites around the world. OCT is responsible for sites in Russia, Ukraine, Belarus, Latvia, Lithuania, Estonia and Bulgaria. In total, our CRO is responsible for more than 60 oncology sites across Eastern Europe.75 % of all patients were enrolled in OCT countries. So we can definitely say that the region where our CRO operates is one of the high recruiting countries in the world.

The clinical study is conducted in patients with recurrent epithelian cancer, primary peritoneal cancer or fallopian tube cancer.
At the end of 2011, successful database lock was performed. We are very pleased to meet this important milestone for our client’s clinical development program. In this study we are responsible for

We will continue to support our client’s clinical program to defeat ovarian cancer. Patients’ enrollment will continue until 650 patients are enrolled.

Ovarian cancer is a disease with few and unspecific symptoms at its early stages, therefore difficult to detect. Unlike certain other cancer diseases the number of patients diagnosed with ovarian cancer increases every year. Ovarian cancer is most often diagnosed in women over 50 years of age, but younger women are also affected. The annual incidence of new diagnosed cases is approximately 125 000 women in EU alone.